Spun off by Naurex after that firm became part of the Allergan acquisition, Aptinyx (NASDAQ:APTX) was launched on the latter's discovery platform for N-methyl-D-aspartic acid (NMDA) modulators with the spinoff owning the parent comapny's medical chemistry and related IP. A clinical-stage biopharmaceutical company, Aptinyx organizes around the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
